We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current DUL market cap is 30.38B. The company's latest EPS is USD -3.4132 and P/E is -72.31.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B |
| Operating Income | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M |
| Net Income | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.4B | 3.41B | 3.64B | 3.55B | 3.83B |
| Total Liabilities | 956.44M | 2.39B | 3.06B | 3.7B | 4.05B |
| Total Equity | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M |
| Investing | -417.68M | -435.52M | -273.3M | 169.35M | -336.35M |
| Financing | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M |
| Market Cap | 30.38B |
| Price to Earnings Ratio | -72.31 |
| Price to Sales Ratio | 17.41 |
| Price to Cash Ratio | 39.17 |
| Price to Book Ratio | -144.27 |
| Dividend Yield | - |
| Shares Outstanding | 128.98M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 3.4 (1.43%) |
| Company Name | Alnylam Pharmace Dl 0001 |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alnylam.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
